Stock Yearly Return 2017
Start date: 01/03/2017
End date: 12/29/2017
Start price/share: $10.15
End price/share: $6.80
Dividends collected/share: $0.00
Total return: -33.00%
CDTX Average Annual Return: -33.46%
Starting investment: $10,000.00
Ending investment: $6,700.00
Years: 0.99


CDTX average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare CDTX average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into CDTX


Also see:
CDTX stock yearly return 2018
CDTX stock yearly return 2019
CDTX stock yearly return 2020
CDTX YTD return
CDTX average annual return 10 years
Cidara Therapeutics is a biotechnology company focused on the discovery, development and commercialization of therapeutics designed for patients facing fungal or viral infections. Co.'s primary product candidate is rezafungin acetate, an intravenous formulation of a echinocandin. Rezafungin is being developed as a once-weekly therapy for the first-line treatment and prevention of invasive fungal infections. In addition, Co. is using its Cloudbreak® platform to develop Antiviral Conjugates, for the prevention and treatment of influenza and other viral infections, including RSV, HIV and the SARS-CoV-2 strains causing COVID-19. The CDTX stock yearly return is shown above.

The yearly return on the CDTX stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2017 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the CDTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for CDTX:
CDTX SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Cidara Therapeutics (CDTX) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CDXC Average Annual Return
CELC Average Annual Return
CELG Average Annual Return
CEMI Average Annual Return
CERC Average Annual Return
CERS Average Annual Return
CFMS Average Annual Return
CFRX Average Annual Return
CGEN Average Annual Return
CGIX Average Annual Return
More Healthcare companies »

 

CDTX Stock Yearly Return 2017 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.